3rd Quarter - Report

THE PAUL LAXALT GROUP for THE ROGOSIN INSTITUTE

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Legislation and regulations relating to Medicare policies that impact care provided to patients with kidney disease.

LobbyistCovered position, as disclosed
TOM LORANGER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Monitor issues concerning improvements in medical research and treatment of kidney disease. Dialysis PATIENTS Demonstration Act of 2017 - HR 4143 and S 2065 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2017 - HR 2644 and S 1980

LobbyistCovered position, as disclosed
TOM LORANGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4143 (115th), H.R. 2644 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.